414 related articles for article (PubMed ID: 8649062)
21. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
Kuti JL; Kotapati S; Williams P; Capitano B; Nightingale CH; Nicolau DP
Pharmacoeconomics; 2004; 22(5):301-10. PubMed ID: 15061680
[TBL] [Abstract][Full Text] [Related]
22. Overview of the lipid formulations of amphotericin B.
Dupont B
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():31-6. PubMed ID: 11801578
[TBL] [Abstract][Full Text] [Related]
23. Amphotericin B formulations and drug targeting.
Torrado JJ; Espada R; Ballesteros MP; Torrado-Santiago S
J Pharm Sci; 2008 Jul; 97(7):2405-25. PubMed ID: 17893903
[TBL] [Abstract][Full Text] [Related]
24. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
25. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.
Groll AH; Müller FM; Piscitelli SC; Walsh TJ
Klin Padiatr; 1998; 210(4):264-73. PubMed ID: 9743964
[TBL] [Abstract][Full Text] [Related]
26. Lipid formulations of amphotericin B as first-line treatment of zygomycosis.
Petrikkos GL
Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():87-92. PubMed ID: 19754765
[TBL] [Abstract][Full Text] [Related]
27. [Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story].
Azanza Perea JR; Barberán J
Rev Esp Quimioter; 2012 Mar; 25(1):17-24. PubMed ID: 22488537
[TBL] [Abstract][Full Text] [Related]
28. Drug delivery system of anti-fungal and parasitic agents.
Maesaki S
Curr Pharm Des; 2002; 8(6):433-40. PubMed ID: 12069380
[TBL] [Abstract][Full Text] [Related]
29. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
[TBL] [Abstract][Full Text] [Related]
30. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
31. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
[TBL] [Abstract][Full Text] [Related]
32. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2002 Mar; 46(3):834-40. PubMed ID: 11850269
[TBL] [Abstract][Full Text] [Related]
33. A brain-vectored angiopep-2 based polymeric micelles for the treatment of intracranial fungal infection.
Shao K; Wu J; Chen Z; Huang S; Li J; Ye L; Lou J; Zhu L; Jiang C
Biomaterials; 2012 Oct; 33(28):6898-907. PubMed ID: 22789719
[TBL] [Abstract][Full Text] [Related]
34. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
[TBL] [Abstract][Full Text] [Related]
35. Lipid formulation as a drug carrier for drug delivery.
Tomii Y
Curr Pharm Des; 2002; 8(6):467-74. PubMed ID: 12069383
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations.
Heinemann V; Kähny B; Debus A; Wachholz K; Jehn U
Bone Marrow Transplant; 1994; 14 Suppl 5():S8-9. PubMed ID: 7703929
[TBL] [Abstract][Full Text] [Related]
37. Lipid-based antifungal agents: current status.
Arikan S; Rex JH
Curr Pharm Des; 2001 Mar; 7(5):393-415. PubMed ID: 11254895
[TBL] [Abstract][Full Text] [Related]
38. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
Falci DR; da Rosa FB; Pasqualotto AC
Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
[TBL] [Abstract][Full Text] [Related]
39. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
Zhang Z; Diener RM; Lipman JM
Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
[TBL] [Abstract][Full Text] [Related]
40. Characterization of amphotericin B liposome formulations.
Manosroi A; Kongkaneramit L; Manosroi J
Drug Dev Ind Pharm; 2004 May; 30(5):535-43. PubMed ID: 15244089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]